Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.

Annals of the Rheumatic Diseases
Shervin AssassiKeith M Sullivan

Abstract

In the randomised scleroderma: Cyclophosphamide Or Transplantation (SCOT trial) (NCT00114530), myeloablation, followed by haematopoietic stem cell transplantation (HSCT), led to improved clinical outcomes compared with monthly cyclophosphamide (CYC) treatment in systemic sclerosis (SSc). Herein, the study aimed to determine global molecular changes at the whole blood transcript and serum protein levels ensuing from HSCT in comparison to intravenous monthly CYC in 62 participants enrolled in the SCOT study. Global transcript studies were performed at pretreatment baseline, 8 months and 26 months postrandomisation using Illumina HT-12 arrays. Levels of 102 proteins were measured in the concomitantly collected serum samples. At the baseline visit, interferon (IFN) and neutrophil transcript modules were upregulated and the cytotoxic/NK module was downregulated in SSc compared with unaffected controls. A paired comparison of the 26 months to the baseline samples revealed a significant decrease of the IFN and neutrophil modules and an increase in the cytotoxic/NK module in the HSCT arm while there was no significant change in the CYC control arm. Also, a composite score of correlating serum proteins with IFN and neutrophil transcript...Continue Reading

References

Jul 3, 2002·The Journal of Experimental Medicine·Sean DiehlMercedes Rincón
Feb 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Emily C BaechlerTimothy W Behrens
Mar 19, 2003·The Journal of Experimental Medicine·Lynda BennettVirginia Pascual
Aug 20, 2003·The Journal of Investigative Dermatology·Toshiyuki Yamamoto, Kiyoshi Nishioka
Oct 28, 2004·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Jan StorekDavid G Maloney
Jan 30, 2010·Arthritis and Rheumatism·Shervin AssassiFilemon K Tan
Apr 5, 2013·Seminars in Immunopathology·Carmelo Carmona-Rivera, Mariana J Kaplan
Jan 28, 2014·Nature Methods·Bo WangAnna Goldenberg
Mar 26, 2014·Nature Reviews. Immunology·Damien Chaussabel, Nicole Baldwin
Jul 25, 2014·JAMA : the Journal of the American Medical Association·Jacob M van LaarUNKNOWN EBMT/EULAR Scleroderma Study Group
Jul 26, 2014·Arthritis Research & Therapy·Lucille DesallaisYannick Allanore
May 19, 2017·Journal of Scleroderma and Related Disorders·Dinesh KhannaChristopher P Denton
Jan 4, 2018·The New England Journal of Medicine·Keith M SullivanUNKNOWN SCOT Study Investigators
Jan 29, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Roni ShouvalAnat Gafter-Gvili
Jan 10, 2019·Arthritis & Rheumatology·Muriel ElhaiYannick Allanore

❮ Previous
Next ❯

Citations

Jan 29, 2020·Clinical and Experimental Immunology·Nila H ServaasJacob M van Laar
Sep 17, 2020·Annals of the Rheumatic Diseases·Jennifer M FranksMichael L Whitfield
Feb 8, 2021·Advances in Rheumatology·Álvaro Henrique-NetoMaria Carolina Oliveira
Jan 22, 2021·Autoimmunity Reviews·Dominique FargeKarin Tarte

Aug 10, 2020·La Revue de médecine interne·A GuffroyV Gies

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.